Riskpilot← Back to searchSign inGet full accessNuclidium (Sweden) AB
ABIn liquidationOrg 5592762933Research and experimental development on biotechnology · NACE 7211Est. 20201 employees
Revenue 2022
SEK 0
EBITDA margin
—
+98% vs 2021
Equity ratio
-132.6%
Financial strength
Net profit 2022
SEK -25K
+98% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -25K | +98% |
| Net profit | SEK -25K | +98% |
| Total assets | SEK 46K | +119% |
| Equity | SEK -61K | -69% |
| Employees | 1 | — |
Legal name
Nuclidium (Sweden) AB
Org number
5592762933
Legal form
Aktiebolag
NACE code
7211 · Research and experimental development on biotechnology
Founded
13 oktober 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Aktiebolaget ska bedriva forskning och utveckling, produktion, service samt handel och försäljning av produkter och tjänster främst till forskning och hälsovård samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | — | — |
| EBITDA | −1 261 | −25 |
| Depreciation & amort. | −0 | −0 |
| EBIT | −1 261 | −25 |
| Net financials | −7 | — |
| Profit before tax | −1 269 | −25 |
| Tax | −0 | −0 |
| Net profit | −1 269 | −25 |
| Item | 2021 | 2022 |
|---|---|---|
| Total assets | 21 | 46 |
| Equity | −36 | −61 |
| Long-term debt | 0 | 0 |
| Short-term debt | 57 | 15 |
| Total debt | 57 | 15 |
EBITDA margin
-2500000.0%
This company
15.8%
Market median
-15822885% vs market
20212022
Equity ratio
-132.6%
This company
38.2%
Market median
-447% vs market
20212022
Return on equity
-2500000.0%
This company
18.4%
Market median
-13587057% vs market
20212022
Net profit margin
-2500000.0%
This company
8.1%
Market median
-30864298% vs market
20212022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212022
Debt / equity
1.75×
This company
0.62×
Market median
-182% vs market
20212022
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CC Liquidator | Liquidator | 2022 |
| Former (1) | ||
EA Liquidator | Liquidator | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (6) | ||
| Deputy Board Member | 2022 – 2023 | |
| Chairman | 2022 – 2023 | |
| Board of Directors | 2020 – 2022 | |
| Chairman | 2020 – 2022 | |
| Deputy Board Member | 2023 – 2023 | |
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nuclidium (Sweden) AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Anders Strömqvist | Liquidator | 0 companies |
| Carl Christofer Daniel Hemsedahl | Liquidator | 0 companies |
| Pasha Razifar | Deputy Board Member | 0 companies |
| Leila Minori Dr. Jaafar | Chairman | 0 companies |
| Anna Maria Lilly Öhman | Board of Directors | 0 companies |
| Lars Wolger Svedin | Chairman | 0 companies |
| Bengt Erik Nilsson Netterlid | Deputy Board Member | 0 companies |
| Siv Inger Backman | Board of Directors | 0 companies |